Eton Pharmaceuticals, Inc. (ETON)Healthcare | Drug Manufacturers - Specialty & Generic | Deer Park, United States | NasdaqGM
25.04 USD
+0.61
(2.497%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 25.04 Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:48 p.m. EDT
Eton Pharmaceuticals (ETON) presents a classic 'watch and wait' scenario with mixed signals despite a 'Strong Buy' consensus driven by massive revenue growth (82%) which hasn't yet translated to profitability (negative EPS). The recent stock volatility and lack of dividends create a low-risk floor for income investors but high risk for short-term momentum traders. While the fundamental thesis on growth is intact, the technicals show mixed options positioning with hedging pressure. It remains a speculative hold/long-term buy candidate but lacks a strong directional catalyst right now. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.260482 |
| AutoETS | 0.262758 |
| AutoARIMA | 0.264285 |
| AutoTheta | 0.279372 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 24.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.151 |
| Excess Kurtosis | -1.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 118.846 |
| Revenue per Share | 2.971 |
| Market Cap | 683,203,712 |
| Forward P/E | 16.05 |
| Beta | 0.97 |
| Profit Margins | -5.76% |
| Website | https://www.etonpharma.com |
As of April 18, 2026, 11:48 p.m. EDT: Options flow indicates a complex neutral-to-bearish deck. In the 4/17 and 5/15 expirations, out-of-the-money (OTM) puts show significantly higher Open Interest (OI) and volume than OTM calls, particularly at the $15-$22.5 strikes, suggesting a hedge or bullish trap is in place near current levels. Conversely, deep ITM long-dated calls in the November expiration show fresh flow (new volume > OI), indicating some leveraged bullish positioning for a significant upside move, though volume remains low. Implied Volatility (IV) in the short-term put chain is elevated (1.13 ATM vs 0.93-0.80 in calls), suggesting the market prices in some downside risk or is placing a bull beta hedge.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7559607 |
| Address1 | 21,925 W. Field Parkway |
| Address2 | Suite 235 |
| All Time High | 27.29 |
| All Time Low | 1.95 |
| Ask | 25.14 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 413,520 |
| Average Daily Volume3 Month | 356,403 |
| Average Volume | 356,403 |
| Average Volume10Days | 413,520 |
| Beta | 0.973 |
| Bid | 24.94 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 0.967 |
| City | Deer Park |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 25.04 |
| Current Ratio | 1.574 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 25.07 |
| Day Low | 24.33 |
| Debt To Equity | 118.846 |
| Display Name | Eton Pharmaceuticals |
| Earnings Call Timestamp End | 1,773,952,200 |
| Earnings Call Timestamp Start | 1,773,952,200 |
| Earnings Timestamp | 1,773,950,400 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | 8,875,000 |
| Ebitda Margins | 0.11101 |
| Enterprise To Ebitda | 77.56 |
| Enterprise To Revenue | 8.61 |
| Enterprise Value | 688,344,640 |
| Eps Current Year | 0.84 |
| Eps Forward | 1.56 |
| Eps Trailing Twelve Months | -0.17 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.396 |
| Fifty Day Average Change | 4.644001 |
| Fifty Day Average Change Percent | 0.22769175 |
| Fifty Two Week Change Percent | 75.59607 |
| Fifty Two Week High | 27.29 |
| Fifty Two Week High Change | -2.25 |
| Fifty Two Week High Change Percent | -0.08244778 |
| Fifty Two Week Low | 13.09 |
| Fifty Two Week Low Change | 11.950001 |
| Fifty Two Week Low Change Percent | 0.91291064 |
| Fifty Two Week Range | 13.09 - 27.29 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,542,119,400,000 |
| Float Shares | 18,288,249 |
| Forward Eps | 1.56 |
| Forward P E | 16.051283 |
| Free Cashflow | 11,161,250 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 44 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.59830004 |
| Gross Profits | 47,834,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04398 |
| Held Percent Institutions | 0.58706003 |
| Implied Shares Outstanding | 27,284,491 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. |
| Long Name | Eton Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 683,203,712 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_435353222 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -4,601,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 682,930,809 |
| Number Of Analyst Opinions | 3 |
| Open | 24.81 |
| Operating Cashflow | 10,524,000 |
| Operating Margins | 0.20986 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 847 787 7361 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 25.04 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 24.43 |
| Price Eps Current Year | 29.809526 |
| Price Hint | 2 |
| Price To Book | 25.89452 |
| Price To Sales Trailing12 Months | 8.545387 |
| Profit Margins | -0.057550002 |
| Quick Ratio | 0.979 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.610001 |
| Regular Market Change Percent | 2.49693 |
| Regular Market Day High | 25.07 |
| Regular Market Day Low | 24.33 |
| Regular Market Day Range | 24.33 - 25.07 |
| Regular Market Open | 24.81 |
| Regular Market Previous Close | 24.43 |
| Regular Market Price | 25.04 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 276,247 |
| Return On Assets | 0.035889998 |
| Return On Equity | -0.18191999 |
| Revenue Growth | 0.827 |
| Revenue Per Share | 2.971 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 27,284,491 |
| Shares Percent Shares Out | 0.0694 |
| Shares Short | 1,894,534 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,217,404 |
| Short Name | Eton Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0729 |
| Short Ratio | 4.56 |
| Source Interval | 15 |
| State | IL |
| Symbol | ETON |
| Target High Price | 52.0 |
| Target Low Price | 31.0 |
| Target Mean Price | 39.33333 |
| Target Median Price | 35.0 |
| Total Cash | 25,942,000 |
| Total Cash Per Share | 0.951 |
| Total Debt | 31,083,000 |
| Total Revenue | 79,950,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.75415 |
| Two Hundred Day Average Change | 7.2858505 |
| Two Hundred Day Average Change Percent | 0.4103745 |
| Type Disp | Equity |
| Volume | 276,247 |
| Website | https://www.etonpharma.com |
| Zip | 60,010-7278 |